Roni Shouval
@RShouval
Precision Cellular Therapy | Attending - BMT and Cellular Therapy Service @sloan_kettering
🚨 Just out @NatureMedicine! Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter nature.com/articles/s4159… 🧵Let’s break it down
Congrats to @KRejeski, @RShouval, and their team on developing a new grading system to evaluate patterns of thrombocytopenia in patients treated with commercial CD19 CAR-T therapy for B-cell non-Hodgkin #lymphoma. @BloodJournal Read the study: bit.ly/42FHRgd
How do gut and oral microbiota shape allogeneic BMT outcomes? In @GenomeMedicine, we introduce RATIO: a novel microbiome-informed machine learning model that predicts post-HCT outcome With @KorenLab, @nagler_EBMT & Oshrit Shtossel. 🔗 genomemedicine.biomedcentral.com/articles/10.11… #HCT #machinelearning
🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH
What is the exact impact of bridging radiation ☢️ (BRT) on CAR T efficacy/safety profile in NHL? BRT is wildly integrated in the bridging regimens but data are limited. Our meta-analysis (>500 pts) addresses this question and now out in @Haematologica haematologica.org/article/view/1…
Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T buff.ly/7a2gj66
Share your latest breakthroughs at the @COSTEMCongress - the premier meeting for cutting-edge debates in hematopoietic stem cell transplantation and cellular therapies. Abstract submission deadline: 15 July! Submit your work👇 itnewsletter.itnewsletter.co.il/sending/webpag…
Updated allogeneic stem cell donor guidelines from the CIBMTR/NMDP. A collaborative effort with many wonderful colleagues. Guidelines are adapted for donor selection when using PTCY. sciencedirect.com/science/articl…
JCI - Clinical, tumor and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma jci.org/articles/view/…
Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by @dgermain21 at #18icml @icmlugano, now available online in Cancer Cell. #lmsm @washumedicine @MDAndersonNews. cell.com/cancer-cell/fu…
We previously showed that IFNg is required for CAR-T efficacy in solid tumors, but is it always good? Here, we show that IFNg limits CD28 CAR-T cells and that protection from this signal drives greater antitumor activity and durability. Enjoy! science.org/doi/10.1126/sc…
🎉Finally out🎉 Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma Now in @BloodPortfolio Timely for #EHA2025🥰 #mmsm ashpublications.org/blood/article/…
Phenomenal work by @thelunar_a. Grateful to @TheIACH for highlighting our study. Read more nature.com/articles/s4140… @BloodCancerJnl.
👂Hear the latest @TheIACH NEWS podcast: CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma by Dr. Alejandro Luna ⬇️⬇️ iach.org/iach-news-podc… @thelunar_a @RShouval @Mohty_EBMT @nagler_EBMT
📢 New Review Out in @Haematologica! Together with Ofrat Beyar Katz and @KRejeski, we discuss hematologic toxicities of CAR-T therapy—definitions, mechanisms, and clinical impact. Read the full review 👉 haematologica.org/article/view/1… #CAR_T #Hematology #Toxicity
Combined #preprint and paper alert! Together with @SohrabShah and @VStrongMD, we have been exploring a fundamental paradox of cancer biology: how can the immune response both suppress and facilitate tumorigenesis? (It's a 2-parter!) biorxiv.org/content/10.110…
🚨New milestone for #CARTcell therapy in #GlobalHematology! We report the first successful decentralized, academic-grade CD19 CAR-T manufacturing in healthy donors in Mexico 🇲🇽 and half a dream come true. 📄 JCO Global Oncology: ascopubs.org/doi/10.1200/GO… 1/🧵👇
Another good example of utilizing the powerful {gtsummary}, {ggsurvfit} and {tidycmprsk} packages for clinical data analysis @MSKBiostats. Congratulations to @KRejeski, Jaime, @RShouval, and team!
One of the more frequent questions we’ve received since the development of the ICAHT grading system is: What about thrombocytopenia after CAR T-cell therapy? We’ve tackled this question head-on in our new paper out now in @BloodJournal 👇 ashpublications.org/blood/article/…
🚨 Check out our new grading system for thrombocytopenia (#T_ICAHT) after #CART doi.org/10.1182/blood.… @BloodJournal Led by Drs. @KRejeski, Jaime Sanz, @StatFei & team — incredible multicenter collaborative effort. See Kai’s 🧵for more insights!
One of the more frequent questions we’ve received since the development of the ICAHT grading system is: What about thrombocytopenia after CAR T-cell therapy? We’ve tackled this question head-on in our new paper out now in @BloodJournal 👇 ashpublications.org/blood/article/…
Excited to share our review on CAR arming of the innate immune cells. Engineering innate immune cells for cancer immunotherapy | Nature Biotechnology nature.com/articles/s4158…